X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Dr. Heather Cheng and Dr. Channing J. Paller

Dr. Cheng is an associate professor, Division of Medical Oncology, Department of Medicine, University of Washington. She is also a faculty member at Fred Hutchinson Cancer Research Center. Dr. Cheng is a lead investigator of the PROMISE study. She focuses on improving the care of patients with prostate and bladder cancers. An expert in prostate cancer genetics, Dr. Cheng is studying ways to use genetics to guide the care of prostate cancer patients and their family members who may also be at high risk for the disease. She leads clinical trials of a variety of new treatments for prostate cancer. Dr. Cheng led the research study: GENTleMEN: GENetic Testing for MEN with metastatic prostate cancer. She is also developing new tests that could help guide doctors’ choice of treatment for each patient and new blood tests to detect and monitor the progression of prostate cancer.

Dr. Paller is associate professor of Oncology and Urology at Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center and associate director for Oncology of the Johns Hopkins Clinical Research Network. She is a clinician scientist focused on translating basic scientific findings into treatments that will improve clinical outcomes and reduce toxicities for men with prostate cancer. Dr. Paller is a lead investigator of the PROMISE study and, as an expert in clinical trial design, she leads multiple clinical trials of innovative new treatments and treatment combinations employing germline and somatic biomarkers. She earned her M.D. at Harvard Medical School and completed her medical residency and fellowship in Medical Oncology at Johns Hopkins.